Patrick Campbell

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Dr. Nisha Parikh provides additional insight into the AHA's latest scientific statement, which highlights the need for greater attention and emphasis on the impact of adverse pregnancy outcomes on cardiovascular risk in women.

An analysis of nearly 150 pregnant women presenting NY-based medical centers suggests prenatal exposure to endocrine-disrupting chemicals in plastics could increase odds of developing postpartum depression.

Announced in a statement by the FDA on April 1, the PCKS9 inhibitor alirocumab is now indicated as an add-on therapy for the treatment of homozygous familial hypercholesterolemia.

An analysis of 2-year data from the DRCR Retina Network's Protocol W study indicates anti-VEGF treatments can delay progression of NPDR to proliferative diabetic retinopathy but was not linked to improvements in visual acuity.

Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

A study from Canada is calling for additional attention to paid to the screening, diagnosis, and treatment of primary aldosteronism in adult patients.

An analysis of DAPA-HF indicates the efficacy and safety profile of dapagliflozin was consistent regardless of patient sex, highlighting the potential of the SGLT2 inhibitor for heart failure patients.

An analysis of the YOUNG-MI registry suggests patients aged 50 or younger who suffer a heart attack were at nearly twice the risk of mortality if they had a diagnosis of a systemic inflammatory disease, such as rheumatoid arthritis and lupus, when compared to their counterparts without an inflammatory disease.

A phase 2 trial examining the effects of daily semaglutide over a 72-week period suggests the GLP1-RA could help patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) achieve NASH resolution.

An analysis of claims data by investigators at University of Pennsylvania indicates DOACs were associated with a 36% lower risk of stroke or systemic embolism and was also associated with a reduction in risk of major bleeding.

An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.

An analysis of data from the Marketscan database suggests undergoing bariatric surgery in severely obese patients with NAFLD could reduce risk of cancer among these patients.

The American Heart Association is highlighting the effect of adverse pregnancy outcomes on risk of cardiovascular disease later in life among women. Check out this interview with the chair of the writing committee for more perspective on the statement.

The FDA announced approval for the Harmony Transcatheter Pulmonary Valve device for treatment of patients with native or surgically-repaired right ventricular outflow tract was awarded to Medtronic Inc.

Data from a single center, retrospective cohort study conducted in Israel suggests undergoing TAVR could lead to improvements in kidney function among patients with aortic stenosis.

A single-center study presented at ENDO 2021 suggests more than half of the patients with thyroid eye disease patients treated with teprotumumab (Tepezza) developed otologic symptoms.

Juan Frias, MD, breaks down results of a post-hoc analysis of the AWARD-11 study examining expanded doses of dulaglutide according to baseline HbA1c levels.

An analysis presented at ENDO 2021 suggests less than 5% of patients at high risk for primary aldosteronism undergo screening and most screenings occur after the onset of symptoms.

An analysis of more than 2k HFrEF patients from the CHAMP-HF registry indicates changes in KCCQ-OS may be a more accurate way of capturing changes in disease state than New York Heart Association class.

An analysis of women with polycystic ovary syndrome indicates Black women with the disorder were at a greater risk for heart disease, diabetes, and stroke than their White counterparts.

Learn more about once-weekly basal insulin Fc from Eli Lilly and Company in this interview with the lead investigator from their phase 2 trial, which was presented at ENDO 2021.

Check out this interview with Louise McCullough, MD, PhD, Program Chair of ISC 21, where she offers perspective on mobile stroke units and what barriers prevent further implementation of the specialized ambulatory units.

Zealand Pharma announced the US FDA approved dasiglucagon (Zegalogue) for treatment of severe hypoglycemia in patients with diabetes aged 6 and older and the injectable will be available as both an auto injector and a prefilled syringe.

A Michigan State University-led analysis suggests just 3% of patients at high risk for primary aldosteronism underwent screening for the hypertensive disorder.

A literature review of studies assessing SGLT2 inhibitor use in kidney transplant patients with diabetes suggests use did not impact graft function and was associated with improvements in glucose control and body weight.

An analysis comparing propensity-matched data from 4k transgender is providing an updated overview of the risk profile for patients undergoing gender-affirming therapy compared to their cisgender counterparts.

A meta-analysis of nearly a dozen studies presented at ENDO 2021 suggests Black women with PCOS were at an increased cardiometabolic risk, despite having comparable fasting glucose and lower triglyceride levels.

A randomized, 3-arm study is giving further insight into the effects of levothyroxine monotherapy compared against a thyroid combination therapy and desiccated thyroid extract for management of hypothyroidism, particularly in patients with Thr92AlaD2 polymorphism.

An analysis of patients and providers from endocrine clinics suggests many patients and providers were open to continuing with telehealth practices after the pandemic and many saw little to no limitations with the new practices.